Dynavax Technologies Corporation clinical trials
Acquired by Sanofi, Feb 10, 2026 · source ↗
The registry lists 25 studies whose lead sponsor is Dynavax Technologies Corporation. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.
- 25studies on the registry
- 0open to participants now
- 2reach primary completion within a year
Before and after it joined Sanofi
- First submitted before Dynavax Technologies Corporation became part of Sanofi
- 25
- First submitted after Dynavax Technologies Corporation became part of Sanofi
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Dynavax Technologies Corporation’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Heplisav-B3 in phase 30 open · 8
- 0 open · 4
- 0 open · 1
Coming up
2 of Dynavax Technologies Corporation’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- 1JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- 1JJun
- JJul
- AAug
- SSep
- OOct
- NNov
All 2
Add all 2 to your calendar (.ics) → With an account.
All 25 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 307
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 4 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
- Dynavax Technologies Corporation25 studies
Something wrong with this grouping? Tell us on the Sanofi page.
Studies
Recruiting first, then most recently updated. Showing 25 of 25. All Sanofi studies →
- Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and OverActive, not recruitingNCT06569823Phase 1/2
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of AgeActive, not recruitingNCT07207408Phase 2
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of AgeCompletedNCT05506969Phase 2
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing HemodialysisCompletedNCT03934736Phase 1
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- DV2-HBV-27: Observational Pregnancy RegistryActive, not recruitingNCT03664648
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult VolunteersCompletedNCT05245838Phase 1
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT02521870Phase 1/2
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) PatientsCompletedNCT00985426Phase 3
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell LymphomaTerminatedNCT02266147Phase 1/2
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLCCompletedNCT03326752Phase 1
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus VaccineCompletedNCT00511095Phase 2
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT00823862Phase 1
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- A Study to Assess DV-601 in Subjects With Chronic Hepatitis BCompletedNCT01023230Phase 1
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal MalesCompletedNCT00599001Phase 1
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic AdultsTerminatedNCT00387738Phase 2
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure ChamberCompletedNCT00537355Phase 2
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal CancerTerminatedNCT00403052Phase 1
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal DiseaseTerminatedNCT00498212Phase 2
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney DiseaseCompletedNCT01282762
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on HemodialysisCompletedNCT01195246Phase 3
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure PatientsCompletedNCT00426712Phase 1
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® VaccineCompletedNCT00435812Phase 3
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- A Study of the Immune Response to Heplisav in Healthy Older AdultsCompletedNCT01999699Phase 1
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® VaccineCompletedNCT02117934Phase 3
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi
- Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B VaccineCompletedNCT01005407Phase 3
Sponsor listed in the registry: Dynavax Technologies Corporation · First submitted before Dynavax Technologies Corporation became part of Sanofi